DocMorris Faces a Two-Sided Test: Voucher Ban in Cologne, Raised Guidance in Zurich
Published on 11/19/2026 at 04:20 | Editorial boerse-global.deA Cologne court ruling and a pair of analyst upgrades landed within days of each other, and together they frame the central question hanging over DocMorris: how much of the company's prescription-drug momentum comes from the digital prescription itself, and how much from the incentives used to pull customers through the door for the first time?
What the Cologne Court Actually Decided
The Landgericht Köln ruled on 10 November in favour of a suit brought by the Apothekerkammer Nordrhein, banning two DocMorris voucher campaigns. Under the promotions, both the referring customer and the new customer were each to receive a EUR 20 voucher, conditional on redeeming an e-prescription for the first time. The judgment is not yet final.
According to the pharmacy chamber's account, the court found no remaining justification for a competitive special position for foreign mail-order pharmacies given changed market conditions.
The scope matters for investors. The ruling targets the two voucher campaigns, not the digital redemption of prescriptions. The dispute begins precisely at the point where the possibility of an online order is meant to become a first actual order. What the judgment leaves unanswered is how persuasive digital redemption is on its own when DocMorris cannot reward that first attempt with these vouchers. It does, however, make plain why rapid growth and freedom in customer acquisition are two separate matters.
Growth Numbers Don't Settle the Sales Question
In October, DocMorris reported growth of more than 90% in its prescription-medication business. Last week the company raised its full-year 2026 revenue growth guidance to around 15%, up from a previously expected range of 12.5% to 15%. For the prescription business specifically, management expects roughly 60% growth in 2026. All other annual and medium-term targets were left unchanged.
Should investors sell immediately? Or is it worth buying DocMorris?
Those figures signal the pace of expansion, but they say nothing about how much individual promotional campaigns contribute to it. Anyone concluding from the new guidance that the voucher dispute is immaterial for DocMorris is reading more into the numbers than they support. Conversely, the ban on the two campaigns permits no inference about growth across the entire prescription business.
Customer Loyalty Is Improving
There is a separate data point worth weighing. New customers at DocMorris ordered roughly twice as often as earlier user groups after the company introduced coverage of statutory co-payments, the Pharmazeutische Zeitung reported yesterday. According to DocMorris, the number of active customers rose by 1.5 million year on year to 13.1 million by the end of September.
Analysts Move, but Not in Unison
Deutsche Bank Research lifted its price target to CHF 22.00 from CHF 17.50 yesterday following the raised revenue guidance, confirming its buy recommendation. Barclays, by contrast, separated a higher target from a higher rating last Friday: analyst Andrew Ross adjusted his estimates to DocMorris's quarterly reports and capital markets day, raising the price target to CHF 19 from CHF 12 while keeping the stock at "Equal Weight."
The shares have climbed 206% since the start of the year. Precisely after such a run, it pays not to confuse a growth figure with an answer to the distribution question.
TeleClinic Adds a Second Growth Leg
Beyond the customer business, DocMorris is expanding its telemedicine offering. On 4 November the company announced that its subsidiary TeleClinic had acquired the Swiss telemedicine provider Medi24. DocMorris expects the acquisition to contribute substantially to TeleClinic's earnings before interest, taxes and depreciation in the first full year, 2027.
The Yardstick That Matters
The more telling test is whether DocMorris can move more customers to a first digital prescription redemption without the two contested voucher campaigns. Only then will it be possible to judge how much pulling power the digital ordering channel has in its own right.
Ad
DocMorris Stock: New Analysis - 19 November
Fresh DocMorris information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
